Ditropan (Oxybutynin)

Anticholinergic for Overactive Bladder and Urinary Incontinence

Rx – Prescription Only ATC: G04BD04 Anticholinergic
Active Ingredient
Oxybutynin hydrochloride
Available Forms
Tablets
Strengths
5 mg
Common Brands
Ditropan
Medically reviewed | Last reviewed: | Evidence level: 1A
Ditropan (oxybutynin) is an anticholinergic medication used to treat overactive bladder symptoms, including urinary urgency, frequent urination, and urge incontinence. It works by relaxing the bladder muscle, reducing involuntary contractions, and increasing bladder capacity. Ditropan is also used for neurogenic bladder dysfunction caused by nervous system disorders, and in children aged 5 and older for bedwetting when other treatments have failed.
Published:
Reading time: 14 minutes
Reviewed:

Quick Facts About Ditropan

Active Ingredient
Oxybutynin
(as hydrochloride)
Drug Class
Anticholinergic
Antimuscarinic Agent
ATC Code
G04BD04
Urinary Antispasmodic
Common Uses
OAB
Overactive Bladder
Available Forms
Tablets
5 mg scored
Prescription Status
Rx Only
Prescription required

Key Takeaways About Ditropan

  • Effective bladder control: Ditropan reduces involuntary bladder contractions, decreasing urinary urgency, frequency, and incontinence episodes
  • Dry mouth is the most common side effect: Occurring in more than 1 in 10 patients, dry mouth can increase the risk of dental cavities and oral infections – maintain thorough dental hygiene
  • Caution in elderly patients: Anticholinergics like oxybutynin carry a higher risk of cognitive side effects (confusion, memory impairment) in older adults
  • Avoid in heat: Ditropan reduces sweating, which can increase the risk of heat exhaustion in hot climates or during intense physical activity
  • Multiple drug interactions: Tell your doctor about all medications you take, especially other anticholinergics, cholinesterase inhibitors for Alzheimer's disease, and antifungal medications

What Is Ditropan and What Is It Used For?

Ditropan (oxybutynin) is an anticholinergic and antispasmodic medication that relaxes the smooth muscle of the urinary bladder. It is primarily used to treat overactive bladder (OAB) symptoms, including urinary urgency, frequent urination, and urge incontinence, as well as neurogenic bladder dysfunction caused by nervous system damage.

Oxybutynin, the active ingredient in Ditropan, belongs to the antimuscarinic class of drugs. It works through a dual mechanism: it exerts a direct antispasmodic (relaxing) effect on the smooth muscle of the detrusor muscle in the bladder wall, and it blocks the action of the neurotransmitter acetylcholine at muscarinic receptors on the bladder muscle. This combined effect reduces the pressure inside the bladder, decreases the frequency and intensity of involuntary bladder contractions, and increases the functional capacity of the bladder.

For patients with overactive bladder (OAB), Ditropan addresses the core symptoms that significantly impact quality of life. Urinary urgency – the sudden, compelling need to urinate that is difficult to defer – is one of the most bothersome symptoms of OAB. Ditropan reduces the strength and frequency of these urges, giving patients more time to reach a bathroom. It also reduces the total number of times a person needs to urinate during the day and night (urinary frequency and nocturia), and helps prevent involuntary leakage of urine (urge incontinence).

In patients with neurogenic bladder dysfunction, the bladder does not function normally due to damage to the nervous system. This may occur as a result of conditions such as spinal cord injury, multiple sclerosis, spina bifida, or other neurological disorders. In these cases, the bladder muscle may contract involuntarily and at inappropriate times, leading to incontinence and potentially dangerous increases in bladder pressure. Ditropan helps relax the overactive detrusor muscle, reducing the risk of complications such as vesicoureteral reflux and kidney damage.

In children aged 5 years and older, Ditropan may be prescribed for urinary incontinence (daytime wetting), increased urinary frequency, and nocturnal enuresis (bedwetting) when non-pharmacological approaches (such as bladder training, alarm therapy, and fluid management) and other medications have not been sufficiently effective. The European Association of Urology (EAU) and the International Children's Continence Society (ICCS) recommend that oxybutynin be used in children only after a thorough evaluation has ruled out underlying structural or neurological causes.

Good to know:

Oxybutynin was first approved for medical use in 1975 and remains one of the most commonly prescribed medications for overactive bladder worldwide. It is available in multiple formulations internationally, including immediate-release tablets, extended-release tablets, transdermal patches, and topical gel, although availability varies by country. The World Health Organization includes oxybutynin on its Model List of Essential Medicines, underscoring its importance in global healthcare.

What Should You Know Before Taking Ditropan?

Before starting Ditropan, inform your doctor about all your medical conditions, especially glaucoma, urinary retention, myasthenia gravis, severe gastrointestinal conditions, and cognitive impairment. Ditropan has several absolute contraindications and requires careful consideration in many patient groups.

Contraindications

You should not take Ditropan if any of the following apply to you:

  • Allergy to oxybutynin hydrochloride or any of the other ingredients in the tablet – symptoms of an allergic reaction may include itching, rash, swelling of the face, lips, tongue or throat, or difficulty breathing
  • Urinary retention (inability to empty the bladder) – including obstruction caused by conditions such as benign prostatic hyperplasia (enlarged prostate), as Ditropan could worsen the obstruction and lead to acute urinary retention
  • Uncontrolled narrow-angle glaucoma (high fluid pressure in the eye) – anticholinergic drugs can further increase intraocular pressure, potentially causing permanent vision damage
  • Myasthenia gravis (severe muscle weakness) – Ditropan may worsen this autoimmune condition by interfering with neuromuscular transmission
  • Gastric retention or severe impairment of gastric emptying – anticholinergics reduce gastrointestinal motility and could worsen this condition
  • Severe ulcerative colitis (chronic inflammatory bowel disease) – reduced bowel motility may precipitate or worsen toxic megacolon
  • Toxic megacolon (severe dilation and inflammation of the colon) – a life-threatening condition that anticholinergics can aggravate
  • Frequent urinary urgency at night caused by heart or kidney disease – in these cases, the underlying condition should be treated rather than the bladder symptoms

Warnings and Precautions

Talk to your doctor or pharmacist before taking Ditropan if you have or have had any of the following conditions. Your doctor will assess whether Ditropan is appropriate for you and may need to monitor you more closely during treatment:

  • High blood pressure (hypertension) – Ditropan may affect cardiovascular function in some patients
  • Heart disease – including arrhythmias, coronary artery disease, or heart failure, as anticholinergics can affect heart rate
  • Hyperthyroidism (overactive thyroid gland) – may increase susceptibility to anticholinergic effects
  • Benign prostatic hyperplasia (enlarged prostate) not causing complete obstruction – requires monitoring for worsening urinary retention
  • Cognitive impairment – difficulties with thinking, memory, comprehension, or perception; anticholinergics may worsen cognitive function, particularly in elderly patients
  • Autonomic neuropathy (nerve disease such as in Parkinson's disease) – the body's ability to compensate for anticholinergic effects may be impaired
  • Hiatal hernia or gastro-oesophageal reflux disease (GORD) – Ditropan can reduce oesophageal motility and worsen reflux symptoms
  • Liver or kidney disease – oxybutynin is metabolised by the liver; impaired hepatic or renal function may lead to increased drug accumulation
  • History of drug or substance misuse – cases of oxybutynin dependency have been reported in patients with a history of substance abuse

Dry mouth is a very common side effect that can increase the risk of dental cavities, gum disease, and oral fungal infections (thrush). It is therefore essential to maintain thorough dental hygiene throughout the entire treatment period, including regular brushing, flossing, and dental check-ups.

Risk of heat exhaustion: Because Ditropan reduces sweating, there is an increased risk of heat-related illness (heat exhaustion or heatstroke) when used in hot climates or during vigorous physical activity. Patients should stay well hydrated and avoid prolonged exposure to high temperatures.

Seek immediate medical attention if you experience:

Swelling of the face, tongue or throat (angioedema), difficulty swallowing, hives (urticaria), or breathing difficulties. Also contact your doctor immediately if your vision suddenly deteriorates or if you develop eye pain, as these may be signs of acute angle-closure glaucoma. Report symptoms such as hallucinations, agitation, confusion, or sleep disturbances to your doctor promptly, as these may be caused by the anticholinergic effects of Ditropan.

Use in Elderly Patients

Ditropan should be used with particular caution in elderly patients. Older adults are more susceptible to anticholinergic side effects, especially those affecting cognitive function, including confusion, disorientation, memory impairment, and delirium. The American Geriatrics Society Beers Criteria and the European Association of Urology (EAU) guidelines both highlight the need for careful risk-benefit assessment before prescribing anticholinergics to elderly patients. If oxybutynin is used, the starting dose should be low and increased gradually, with regular monitoring for cognitive changes.

Use in Children

Ditropan is not recommended for children under 5 years of age, as safety and efficacy have not been established in this age group. In children aged 5 years and older, Ditropan should be used with caution, as younger patients may be more susceptible to anticholinergic side effects including central nervous system effects. Treatment should be initiated at the lowest effective dose, and children should be monitored regularly for adverse effects including changes in behaviour, mood, or cognitive function.

Pregnancy and Breastfeeding

There is limited clinical data on the use of oxybutynin during pregnancy in humans. Because of this uncertainty, Ditropan is not recommended during pregnancy unless your doctor considers it absolutely necessary and the potential benefits outweigh the possible risks to the developing baby. If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor before taking Ditropan.

Oxybutynin passes into breast milk, although the amount transferred to a breastfed infant and its clinical significance are not well characterised. Breastfeeding is generally not recommended during treatment with Ditropan unless your doctor advises otherwise after considering the benefits and risks.

Driving and Operating Machinery

Ditropan can cause drowsiness, dizziness, and blurred vision, which may impair your ability to drive safely or operate machinery. These effects are more likely at the start of treatment, after dose increases, or when combined with alcohol or other sedating medications. If you experience any of these symptoms, you should not drive, operate machinery, or perform activities requiring alertness until the symptoms have fully resolved. You are responsible for assessing whether you are fit to perform these activities while taking this medication.

Alcohol

Alcohol can increase the drowsiness caused by Ditropan. If you consume alcoholic beverages while taking this medication, the sedative effects may be more pronounced. It is advisable to limit or avoid alcohol consumption during treatment, particularly until you know how Ditropan affects you individually.

Important Information About Excipients

Ditropan tablets contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine.

How Does Ditropan Interact with Other Drugs?

Ditropan can interact with a wide range of medications, particularly other anticholinergic drugs, cholinesterase inhibitors used for Alzheimer's disease, antifungal agents, macrolide antibiotics, and drugs that affect gastrointestinal motility. Always tell your doctor about all medications you take, including over-the-counter products and herbal supplements.

Because oxybutynin has anticholinergic properties, its effects can be additive or synergistic with other drugs that also have anticholinergic activity. Conversely, drugs that increase cholinergic activity (such as cholinesterase inhibitors) may have their effectiveness reduced by concurrent use of oxybutynin. Oxybutynin is metabolised primarily by the CYP3A4 enzyme in the liver, meaning that drugs which inhibit or induce this enzyme can alter oxybutynin blood levels.

Major Interactions

Major Drug Interactions with Ditropan
Drug / Class Category Effect Recommendation
Donepezil, Rivastigmine, Galantamine Cholinesterase inhibitors (Alzheimer's) Ditropan opposes the action of these drugs, reducing their effectiveness in treating dementia Avoid combination if possible; consult a specialist
Other anticholinergics (biperiden, atropine, tricyclic antidepressants, phenothiazines, butyrophenones, clozapine) Anticholinergic medications Additive anticholinergic effects: increased risk of dry mouth, constipation, urinary retention, confusion, delirium Minimise anticholinergic burden; use lowest effective doses
Sublingual nitrates (glyceryl trinitrate) Angina treatment Dry mouth caused by Ditropan may impair sublingual absorption of nitrate tablets Moisten the mouth before placing sublingual tablets; consider nitrate spray as alternative

Moderate Interactions

Moderate Drug Interactions with Ditropan
Drug / Class Category Effect Recommendation
Ketoconazole, Itraconazole Antifungal agents CYP3A4 inhibitors that increase oxybutynin blood levels, potentially increasing side effects Monitor for increased anticholinergic effects; dose reduction may be needed
Erythromycin, Clarithromycin Macrolide antibiotics CYP3A4 inhibitors that may increase oxybutynin plasma concentrations Monitor for adverse effects during concurrent use
Metoclopramide, Domperidone Prokinetic agents (anti-nausea) Ditropan opposes the gastrointestinal motility-enhancing effects of these drugs, and vice versa Effectiveness of both drugs may be reduced; consult your doctor
Levodopa Parkinson's disease treatment Oxybutynin may reduce the absorption of levodopa by slowing gastric emptying Monitor Parkinson's symptoms; timing of doses may need adjustment
Digoxin Heart medication Anticholinergic effects may alter digoxin absorption Monitor digoxin levels; watch for signs of toxicity or loss of efficacy
Amitriptyline, Nortriptyline Tricyclic antidepressants Additive anticholinergic effects; both drugs can cause dry mouth, constipation, urinary retention, and cognitive impairment Use with caution; monitor for excessive anticholinergic effects

Urinary tract infections that develop during treatment with oxybutynin should be treated with appropriate antibiotics. Your doctor will select an antibiotic that does not significantly interact with Ditropan.

What Is the Correct Dosage of Ditropan?

The usual starting dose for adults is 2.5 mg (half a tablet) three times daily, which may be gradually increased to a maximum of 20 mg per day. Dosage is individualised based on response and tolerability. Always follow your doctor's dosing instructions.

Always take Ditropan exactly as your doctor or pharmacist has instructed you. Do not change your dose without consulting your doctor first. Ditropan tablets can be taken before meals and should be swallowed whole or halved (using the score line) with half a glass of water. The tablets have a bitter taste and should not be chewed.

Adults

Overactive Bladder / Urinary Incontinence

Starting dose: 2.5 mg (half a tablet) three times daily

Maximum dose: 20 mg per day, divided into 2–3 doses

Your doctor will start with a low dose and increase it gradually to find the lowest effective dose that provides adequate symptom control with acceptable side effects. Typical dose adjustments are made in increments of 2.5 mg every 1–2 weeks. Most patients achieve satisfactory symptom control at doses of 5 mg two to three times daily.

Elderly Patients

Adjusted Starting Dose

Starting dose: 2.5 mg twice daily

The elimination half-life of oxybutynin may be prolonged in some elderly patients, leading to higher blood levels with standard doses. Your doctor will individualise the dose, starting low and titrating carefully based on your response and the occurrence of side effects. Regular review of the need for continued treatment is recommended in this age group.

Children (5 Years and Older)

Ditropan Dosage for Children
Age Group Dosage Notes
5–9 years 2.5 mg three times daily Maximum dose related to body weight (0.3–0.4 mg/kg/day)
9–12 years 5 mg twice daily Adjust based on individual response and tolerability
Over 12 years 5 mg three times daily Same maximum dose as adults (20 mg/day)

The usual starting dose for children aged 5 and older is 2.5 mg (half a tablet) twice daily. Your child's doctor will adjust the dose based on the child's weight, age, and response to treatment, up to a weight-based maximum of 0.3–0.4 mg/kg per day. Ditropan is not recommended for children under 5 years of age.

Missed Dose

If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the one you missed. If you frequently forget doses, consider setting reminders or aligning your doses with regular daily activities such as meals.

Overdose

If you or someone else takes too much Ditropan:

Contact your doctor, go to the nearest hospital emergency department, or call your local poison control centre immediately. Symptoms of overdose may include severe restlessness or agitation, hot flushes, dizziness or lightheadedness, very fast, irregular or forceful heartbeat, a drop in blood pressure, breathing difficulties, numbness, or loss of consciousness (coma). Take the medication package with you to show the healthcare provider.

What Are the Side Effects of Ditropan?

Like all medicines, Ditropan can cause side effects, although not everyone experiences them. The most common side effects are anticholinergic in nature and include dry mouth, constipation, blurred vision, dizziness, headache, drowsiness, nausea, and dry skin. Most side effects are dose-dependent and may improve with dose reduction.

The side effects of Ditropan are largely related to its anticholinergic mechanism of action. By blocking muscarinic acetylcholine receptors throughout the body (not just in the bladder), oxybutynin can affect multiple organ systems, including the eyes, mouth, gastrointestinal tract, skin, heart, and central nervous system. Understanding these side effects helps you and your doctor make informed decisions about treatment and manage any problems that arise.

Very Common

May affect more than 1 in 10 people
  • Dry mouth (xerostomia)
  • Dizziness
  • Headache
  • Blurred vision
  • Nausea
  • Constipation
  • Dry skin
  • Fatigue (tiredness)

Common

May affect up to 1 in 10 people
  • Confusion
  • Dry eyes
  • Facial flushing
  • Hot flushes
  • Diarrhoea
  • Vomiting
  • Difficulty urinating (urinary hesitancy)
  • Drowsiness (somnolence)
  • Palpitations (fast or irregular heartbeat)

Uncommon

May affect up to 1 in 100 people
  • Loss of appetite (anorexia)
  • Difficulty swallowing (dysphagia)
  • Abdominal discomfort or pain

Rare

May affect up to 1 in 1,000 people
  • Agitation or restlessness
  • Sensitivity to sunlight (photosensitivity)
  • Erectile dysfunction (impotence)

Not Known

Frequency cannot be estimated from available data
  • Urinary tract infection
  • Hypersensitivity reactions
  • Nightmares, hallucinations, paranoia
  • Anxiety, agitation, feeling of unease
  • Seizures (convulsions)
  • Pupil dilation (mydriasis)
  • Increased eye pressure, glaucoma
  • Palpitations, cardiac arrhythmia
  • Acid reflux (gastro-oesophageal reflux)
  • Intestinal obstruction (ileus)
  • Skin rash, urticaria (hives), angioedema
  • Heatstroke, decreased sweating
  • Oxybutynin dependence (in patients with prior substance misuse)
  • Depression, nosebleeds (epistaxis)
  • Muscle weakness or muscle pain
  • Cognitive impairment (especially in elderly patients)
Managing dry mouth:

Dry mouth is the most frequently reported side effect and can significantly impact quality of life. To help manage it: sip water frequently throughout the day, use sugar-free chewing gum or lozenges to stimulate saliva production, maintain meticulous oral hygiene (brush twice daily with fluoride toothpaste, floss regularly), attend regular dental check-ups, and consider over-the-counter saliva substitutes. Limiting caffeine and alcohol can also help, as both can worsen dry mouth.

If any side effects become severe, or if you notice effects not listed above, contact your doctor or pharmacist promptly. Reporting suspected adverse reactions is important for ongoing monitoring of the medicine's benefit-risk balance.

How Should You Store Ditropan?

Store Ditropan at a temperature below 30°C, in the original packaging, and keep it out of reach and sight of children. Do not use the medication after the expiry date printed on the package.

Proper storage is essential to maintain the effectiveness and safety of your medication. Keep Ditropan tablets in their original blister packaging to protect them from moisture and light. Store at room temperature, not exceeding 30°C. Do not store the tablets in the bathroom or other humid environments, as moisture can degrade the active ingredient.

Check the expiry date on the carton and blister pack before use. The expiry date refers to the last day of the stated month. Do not use Ditropan after this date, as the medication may no longer be effective or safe.

Do not dispose of unused or expired medicines via household waste or by flushing them down the drain. Return any unwanted medication to your local pharmacy for safe disposal. This helps protect the environment from pharmaceutical contamination.

What Does Ditropan Contain?

Each Ditropan tablet contains 5 mg of oxybutynin hydrochloride as the active substance. The tablets also contain inactive ingredients including anhydrous lactose, microcrystalline cellulose, and calcium stearate.

Active Substance

The active ingredient is oxybutynin hydrochloride. Each tablet contains 5 mg of oxybutynin hydrochloride, equivalent to approximately 4.5 mg of oxybutynin base.

Inactive Ingredients (Excipients)

The other ingredients are:

  • Anhydrous lactose – a sugar-based filler (important for patients with lactose intolerance)
  • Microcrystalline cellulose – provides bulk and binding properties to the tablet
  • Calcium stearate – acts as a lubricant during the tablet manufacturing process

Appearance and Packaging

Ditropan tablets are white, round, and convex, with a score line on one side and marked with “OXB 5” on the other side. The tablets have a diameter of approximately 8 mm. The score line allows the tablet to be divided into equal halves for dose adjustment. Ditropan is available in blister packs of 20 or 100 tablets. Not all pack sizes may be marketed in every country.

Frequently Asked Questions About Ditropan

Ditropan (oxybutynin) is used to treat overactive bladder symptoms including urinary urgency, frequent urination, and urge incontinence. It also treats neurogenic bladder dysfunction caused by nervous system disorders. In children aged 5 and older, it may be used for urinary incontinence and bedwetting when other treatments have failed. Ditropan works by relaxing the bladder muscle, reducing involuntary contractions, and increasing bladder capacity.

The most common side effects of Ditropan include dry mouth (affecting more than 1 in 10 people), constipation, blurred vision, dizziness, headache, drowsiness, nausea, and dry skin. Dry mouth is the most frequently reported side effect and can increase the risk of dental cavities and oral thrush. Most anticholinergic side effects are dose-dependent and may improve with dose adjustment or over time.

Ditropan should be used with caution in elderly patients. Older adults are more susceptible to anticholinergic side effects, particularly cognitive impairment including confusion, memory problems, and disorientation. International guidelines recommend careful risk-benefit assessment before prescribing anticholinergics to elderly patients. Lower starting doses (2.5 mg twice daily) and regular cognitive monitoring are advised. Your doctor may consider alternative medications with fewer cognitive effects, such as mirabegron (a beta-3 agonist).

Ditropan typically begins to show effects within 1 to 2 weeks of starting treatment, although some patients may notice improvements in urgency and frequency within the first few days. The full therapeutic benefit may take 4 to 6 weeks to develop as the dose is gradually increased. If no significant improvement is seen after 8 weeks at the maximum tolerated dose, your doctor may consider alternative treatments or additional investigations.

There is limited data on the safety of Ditropan during pregnancy, and it is not recommended unless your doctor considers it absolutely necessary. Oxybutynin does pass into breast milk, and breastfeeding is generally not recommended while taking Ditropan. If you are pregnant, planning to become pregnant, or breastfeeding, always discuss your treatment options with your doctor before starting or continuing Ditropan.

Ditropan causes dry mouth because it blocks muscarinic acetylcholine receptors in the salivary glands, reducing saliva production. To manage this: sip water frequently, use sugar-free gum or lozenges to stimulate saliva, maintain excellent dental hygiene (as dry mouth raises the risk of cavities and fungal infections), and consider saliva substitute products available at pharmacies. Limiting caffeine and alcohol can also help. If dry mouth is severe and intolerable, discuss dose adjustment or alternative medications with your doctor.

References

  1. European Association of Urology (EAU). Guidelines on Urinary Incontinence in Adults. 2024 Edition. Available at: uroweb.org
  2. American Urological Association (AUA) / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558–563.
  3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178.
  4. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.
  5. Coupland CAC, Hill T, Dening T, et al. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019;179(8):1084–1093.
  6. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052–2081.
  7. World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
  8. Electronic Medicines Compendium (EMC). Ditropan 5 mg Tablets – Summary of Product Characteristics. Available at: medicines.org.uk
  9. National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline [NG123]. 2019 (updated 2024).
  10. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.

Editorial Team

This article has been written and medically reviewed by the iMedic Medical Editorial Team, which includes licensed specialist physicians in urology, clinical pharmacology, and internal medicine. All medical content is based on current international guidelines, peer-reviewed research, and clinical evidence.

Medical Writing

Written by the iMedic content team following established medical journalism standards. All information is cross-referenced with multiple authoritative sources including the EAU, AUA, NICE, and WHO guidelines.

Medical Review

Reviewed by the iMedic Medical Review Board, an independent panel of board-certified physicians who ensure accuracy, completeness, and adherence to the GRADE evidence framework.

Last reviewed: | Next review due: | Evidence level: 1A